Fulcrum Total Assets vs Free Cash Flow per Share Analysis

FULC Stock  USD 9.46  0.33  3.61%   
Fulcrum Therapeutics financial indicator trend analysis is much more than just examining Fulcrum Therapeutics latest accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Fulcrum Therapeutics is a good investment. Please check the relationship between Fulcrum Therapeutics Total Assets and its Free Cash Flow Per Share accounts. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Fulcrum Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of economic analysis.
For information on how to trade Fulcrum Stock refer to our How to Trade Fulcrum Stock guide.

Total Assets vs Free Cash Flow Per Share

Total Assets vs Free Cash Flow per Share Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Fulcrum Therapeutics Total Assets account and Free Cash Flow per Share. At this time, the significance of the direction appears to have no relationship.
The correlation between Fulcrum Therapeutics' Total Assets and Free Cash Flow per Share is 0.01. Overlapping area represents the amount of variation of Total Assets that can explain the historical movement of Free Cash Flow per Share in the same time period over historical financial statements of Fulcrum Therapeutics, assuming nothing else is changed. The correlation between historical values of Fulcrum Therapeutics' Total Assets and Free Cash Flow per Share is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Total Assets of Fulcrum Therapeutics are associated (or correlated) with its Free Cash Flow per Share. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Free Cash Flow per Share has no effect on the direction of Total Assets i.e., Fulcrum Therapeutics' Total Assets and Free Cash Flow per Share go up and down completely randomly.

Correlation Coefficient

0.01
Relationship DirectionPositive 
Relationship StrengthInsignificant

Total Assets

Total assets refers to the total amount of Fulcrum Therapeutics assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in Fulcrum Therapeutics books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. The total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets.

Free Cash Flow Per Share

The amount of cash a company generates after accounting for capital expenditures, divided by the number of outstanding shares. It represents the cash available for dividends, share buybacks, or debt repayment per share.
Most indicators from Fulcrum Therapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Fulcrum Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Fulcrum Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of economic analysis.
For information on how to trade Fulcrum Stock refer to our How to Trade Fulcrum Stock guide.As of March 28, 2024, Selling General Administrative is expected to decline to about 25.3 M. In addition to that, Issuance Of Capital Stock is expected to decline to about 113.7 M
 2018 2019 2023 2024 (projected)
Interest Income518K1.5M1.7M1.8M
Net Interest Income518K1.5M1.7M1.8M

Fulcrum Therapeutics fundamental ratios Correlations

0.690.811.00.260.930.27-0.42-0.930.810.540.87-0.030.91.00.810.950.920.830.93-0.520.890.990.871.00.7
0.690.710.660.230.710.39-0.32-0.760.520.450.85-0.170.780.680.360.740.710.840.74-0.470.510.760.80.670.57
0.810.710.780.50.810.27-0.51-0.740.930.590.84-0.050.720.810.850.770.660.760.78-0.70.580.780.970.80.49
1.00.660.780.220.930.24-0.38-0.920.790.510.85-0.010.91.00.810.940.930.80.93-0.50.910.990.831.00.71
0.260.230.50.220.140.74-0.95-0.040.280.880.39-0.680.090.260.270.15-0.060.560.080.1-0.110.180.550.290.08
0.930.710.810.930.140.28-0.25-0.970.840.410.78-0.050.920.940.780.960.870.760.99-0.510.860.940.840.920.75
0.270.390.270.240.740.28-0.74-0.190.090.750.32-0.960.230.26-0.030.260.010.640.230.460.030.230.430.290.23
-0.42-0.32-0.51-0.38-0.95-0.25-0.740.2-0.29-0.98-0.560.63-0.29-0.41-0.29-0.32-0.11-0.71-0.22-0.06-0.05-0.33-0.61-0.45-0.25
-0.93-0.76-0.74-0.92-0.04-0.97-0.190.2-0.73-0.38-0.83-0.06-0.98-0.92-0.7-0.99-0.93-0.77-0.990.56-0.84-0.95-0.8-0.91-0.84
0.810.520.930.790.280.840.09-0.29-0.730.370.680.10.650.810.910.740.670.590.78-0.680.730.770.850.790.38
0.540.450.590.510.880.410.75-0.98-0.380.370.68-0.590.470.530.350.490.260.820.4-0.020.180.470.710.580.42
0.870.850.840.850.390.780.32-0.56-0.830.680.68-0.040.880.860.620.870.790.930.82-0.60.640.870.920.870.66
-0.03-0.17-0.05-0.01-0.68-0.05-0.960.63-0.060.1-0.59-0.040.04-0.030.210.00.21-0.410.02-0.660.150.0-0.18-0.05-0.01
0.90.780.720.90.090.920.23-0.29-0.980.650.470.880.040.90.630.990.890.830.96-0.550.770.920.80.90.88
1.00.680.811.00.260.940.26-0.41-0.920.810.530.86-0.030.90.820.940.920.820.93-0.520.90.990.861.00.7
0.810.360.850.810.270.78-0.03-0.29-0.70.910.350.620.210.630.820.720.710.490.74-0.70.70.770.760.80.5
0.950.740.770.940.150.960.26-0.32-0.990.740.490.870.00.990.940.720.90.830.99-0.530.830.950.840.940.85
0.920.710.660.93-0.060.870.01-0.11-0.930.670.260.790.210.890.920.710.90.680.9-0.610.890.960.710.910.73
0.830.840.760.80.560.760.64-0.71-0.770.590.820.93-0.410.830.820.490.830.680.78-0.290.570.820.90.840.65
0.930.740.780.930.080.990.23-0.22-0.990.780.40.820.020.960.930.740.990.90.78-0.550.850.940.820.920.81
-0.52-0.47-0.7-0.50.1-0.510.46-0.060.56-0.68-0.02-0.6-0.66-0.55-0.52-0.7-0.53-0.61-0.29-0.55-0.43-0.54-0.58-0.49-0.37
0.890.510.580.91-0.110.860.03-0.05-0.840.730.180.640.150.770.90.70.830.890.570.85-0.430.90.610.880.51
0.990.760.780.990.180.940.23-0.33-0.950.770.470.870.00.920.990.770.950.960.820.94-0.540.90.840.980.72
0.870.80.970.830.550.840.43-0.61-0.80.850.710.92-0.180.80.860.760.840.710.90.82-0.580.610.840.860.58
1.00.670.81.00.290.920.29-0.45-0.910.790.580.87-0.050.91.00.80.940.910.840.92-0.490.880.980.860.71
0.70.570.490.710.080.750.23-0.25-0.840.380.420.66-0.010.880.70.50.850.730.650.81-0.370.510.720.580.71
Click cells to compare fundamentals

Fulcrum Therapeutics Account Relationship Matchups

Fulcrum Therapeutics fundamental ratios Accounts

201920202021202220232024 (projected)
Total Assets110.4M129.6M235M226.7M257.7M164.9M
Other Current Liab5.9M7.7M74K9.6M8.7M5.2M
Total Current Liabilities12.1M26.7M19.2M16.7M13.7M15.0M
Total Stockholder Equity87.2M95.2M211.5M198.9M235.2M142.3M
Other Liab11.1M7.7M4.3M197K177.3K168.4K
Net Tangible Assets87.2M95.2M211.5M198.9M228.8M240.2M
Property Plant And Equipment Net87.9M8.4M7.4M16.0M12.4M16.6M
Net Debt(96.7M)(57.0M)(35.4M)(21.7M)(14.7M)(15.5M)
Retained Earnings(150.8M)(221.6M)(302.5M)(412.3M)(509.7M)(484.2M)
Accounts Payable2.2M4.1M4.8M3.6M2.8M3.2M
Cash96.7M57.1M35.4M35.1M25.6M36.9M
Non Current Assets Total10.4M16.7M9.0M19.2M15.5M13.4M
Non Currrent Assets Other(78.7M)7.2M542K2.1M2.0M2.1M
Other Assets1.2M1.7M1.6M3.2M3.7M3.9M
Cash And Short Term Investments96.7M112.9M218.2M202.9M236.2M147.7M
Net Receivables111K2.7M4.1M1.1M2.2M1.7M
Common Stock Total Equity23K28K41K52K59.8K62.8K
Common Stock Shares Outstanding11.0M25.4M35.4M45.0M61.3M32.4M
Liabilities And Stockholders Equity110.4M129.6M235M226.7M257.7M164.9M
Non Current Liabilities Total11.1M7.7M4.3M11.0M8.8M7.7M
Capital Surpluse237.9M316.8M514.4M612.0M703.8M739.0M
Capital Lease Obligations46K50K17K13.4M10.8M11.4M
Inventory3.0M(2.8M)(473K)(852K)(766.8K)(728.5K)
Other Current Assets284K74K4.2M4.4M3.7M2.1M
Other Stockholder Equity237.9M316.8M514.4M612.0M744.9M404.7M
Total Liab23.3M34.4M23.5M27.7M22.5M22.7M
Net Invested Capital87.2M95.2M211.5M198.9M235.2M136.8M
Property Plant And Equipment Gross9.2M8.4M7.4M6.9M25.2M26.4M
Total Current Assets100.1M112.9M226.0M207.5M242.2M151.5M
Accumulated Other Comprehensive Income(110.4M)(2K)(397K)(797K)(136K)(142.8K)
Non Current Liabilities Other150K55K3.1M197K226.6K215.2K
Net Working Capital87.9M92.8M206.8M190.8M228.5M137.5M
Short Term Debt50K17K9.6M2.6M2.2M2.3M
Common Stock23K28K41K52K62K35.0K
Property Plant Equipment9.2M8.4M7.4M6.9M7.9M8.3M
Short Long Term Debt Total50K17K469K13.4M10.8M11.4M
Current Deferred Revenue4.0M14.9M4.7M934K840.6K798.6K
Capital Stock23K28K41K52K62K40.7K

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect
When determining whether Fulcrum Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Fulcrum Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Fulcrum Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Fulcrum Therapeutics Stock:
Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Fulcrum Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of economic analysis.
For information on how to trade Fulcrum Stock refer to our How to Trade Fulcrum Stock guide.
You can also try the Money Flow Index module to determine momentum by analyzing Money Flow Index and other technical indicators.

Complementary Tools for Fulcrum Stock analysis

When running Fulcrum Therapeutics' price analysis, check to measure Fulcrum Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Fulcrum Therapeutics is operating at the current time. Most of Fulcrum Therapeutics' value examination focuses on studying past and present price action to predict the probability of Fulcrum Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Fulcrum Therapeutics' price. Additionally, you may evaluate how the addition of Fulcrum Therapeutics to your portfolios can decrease your overall portfolio volatility.
Equity Analysis
Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities
Commodity Channel
Use Commodity Channel Index to analyze current equity momentum
Idea Analyzer
Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas
Share Portfolio
Track or share privately all of your investments from the convenience of any device
Equity Valuation
Check real value of public entities based on technical and fundamental data
Is Fulcrum Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Fulcrum Therapeutics. If investors know Fulcrum will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Fulcrum Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(1.59)
Revenue Per Share
0.046
Quarterly Revenue Growth
0.272
Return On Assets
(0.29)
Return On Equity
(0.45)
The market value of Fulcrum Therapeutics is measured differently than its book value, which is the value of Fulcrum that is recorded on the company's balance sheet. Investors also form their own opinion of Fulcrum Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Fulcrum Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Fulcrum Therapeutics' market value can be influenced by many factors that don't directly affect Fulcrum Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Fulcrum Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Fulcrum Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Fulcrum Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.